HOLLOW FIBER BIOREACTOR WITH IMPROVED OXYGENATION

重组研究促进了Mmlian的体外生产 细胞分泌产物。这些产品用于体外培养和生产中。 活体诊断和治疗环境。已经被 已获批准或正在审批过程中预测了以下市场需求 每年100公斤的订单。大型企业的需求 像这样的数量，用今天的状态很难生产 细胞培养的艺术方法。 开发了一种新型的中空纤维生物反应器，可以满足这些要求。 以具有成本效益的方式满足生产需求。该设备具有所有 中空纤维细胞培养的优势；高细胞密度，低培养 体积大，产品浓度高，纯度高，血清/生长因子低 要求和紧凑的尺寸。 生物反应器是一种新颖的设计，很容易在不需要的情况下制造 在资本设备上的大量投资，并可线性扩展。这个 装置能以196 mm/小时/升(K1a=3920)的速度输送氧气 小时=1)。 建议的第一阶段研究目标是生成数据 要求优化商业生物反应器的设计。这 生物反应器将允许超大规模哺乳动物细胞以更少的空间 与当今最先进的设备相比，设备成本更低 细胞培养方法。这项研究将导致第二阶段的开发 商用生物反应器，为改良细胞奠定基础 文化仪器的发展。

Recombinant research has facilitated the in vitro production of mmmlian cell secreted products. These products are used in the invitro and in vivo diagnostic and therapeutic setting. Products that have been approved or are in the appr-oval process have projected market needs on the order of 100 kilogram per year. The requirerwnts of large quantities, like this, will be difficult to produce using today's state of the art cell culture methods. A new hollow fiber bioreactor has been developed that can meet these production needs in a cost effective manner. The device has all of the advantages of hollow fiber cell culture; high cell density, low culture volumes, high product concentration and purity, low serum/growth factor requirement and compact size. The bioreactor is a novel design, that is easily manufacttured without large investments in capital equipment and is linearly scalable. The device can transfer oxygen at a rate of 196 mM/hour/liter (K1a=3920 hrs=1). The proposed Phase I research objective is to gbenerate the data required to optimize the design of the commercial bioreactor. This bioreactyor will allow very large scale mammalian cell with less space and reduced equipment costs when compared to today's state of the art cell culture methods. This research will lead to Phase II development of the commercial bioreactor and lay the groundwork for improved cell culture instrumentation development.